- Home
- NAGE vs VNDA Comparison
NAGE vs VNDA Comparison
Compare NAGE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | VNDA |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 474.0M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NAGE | VNDA |
|---|---|---|
| Price | $4.86 | $9.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.00 | $14.90 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $20.75 | $21.50 |
| Revenue Next Year | $19.96 | $38.67 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.73 | $3.81 |
| 52 Week High | $14.66 | $9.91 |
Technical Indicators
Market Signals| Indicator | NAGE | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 63.43 |
| Support Level | $4.73 | $7.39 |
| Resistance Level | $5.32 | N/A |
| Average True Range (ATR) | 0.28 | 0.59 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 11.37 | 86.63 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.